Is Pacific Biosciences Stock a Good Investment?
Pacific Biosciences Investment Advice | PACB |
- Examine Pacific Biosciences' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Pacific Biosciences' leadership team and their track record. Good management can help Pacific Biosciences navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Life Sciences Tools & Services space and any emerging trends that could impact Pacific Biosciences' business and its evolving consumer preferences.
- Compare Pacific Biosciences' performance and market position to its competitors. Analyze how Pacific Biosciences is positioned in terms of product offerings, innovation, and market share.
- Check if Pacific Biosciences pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Pacific Biosciences' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Pacific Biosciences of stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Pacific Biosciences of is a good investment.
Sell | Buy |
Strong Sell
Market Performance | OK | Details | |
Volatility | Risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Pacific Biosciences Stock
Researching Pacific Biosciences' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 83.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.17. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Pacific Biosciences has Price/Earnings (P/E) ratio of 197.88. The entity recorded a loss per share of 1.46. The firm had not issued any dividends in recent years.
To determine if Pacific Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Pacific Biosciences' research are outlined below:
| Pacific Biosciences is way too risky over 90 days horizon | |
| Pacific Biosciences may become a speculative penny stock | |
| Pacific Biosciences appears to be risky and price may revert if volatility continues | |
| Pacific Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 200.52 M. Net Loss for the year was (306.74 M) with profit before overhead, payroll, taxes, and interest of 53.47 M. | |
| Pacific Biosciences of currently holds about 834.34 M in cash with (259.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.69, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Pacific Biosciences has a frail financial position based on the latest SEC disclosures | |
| Over 83.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Pacific Biosciences of California, Inc. Among the Best Genomics Stocks to Buy Right Now |
Pacific Biosciences Quarterly Liabilities And Stockholders Equity |
|
Pacific Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Pacific Biosciences of. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Pacific Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 15th of February 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Pacific Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Pacific Biosciences' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2018-02-01 | 2017-12-31 | -0.2 | -0.18 | 0.02 | 10 | ||
2015-08-05 | 2015-06-30 | -0.14 | -0.16 | -0.02 | 14 | ||
2022-02-15 | 2021-12-31 | -0.28 | -0.31 | -0.03 | 10 | ||
2020-08-03 | 2020-06-30 | -0.18 | -0.15 | 0.03 | 16 | ||
2014-10-23 | 2014-09-30 | -0.16 | -0.13 | 0.03 | 18 | ||
2023-08-02 | 2023-06-30 | -0.32 | -0.28 | 0.04 | 12 | ||
2019-11-07 | 2019-09-30 | -0.15 | -0.19 | -0.04 | 26 | ||
2018-11-01 | 2018-09-30 | -0.15 | -0.19 | -0.04 | 26 |
Know Pacific Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Pacific Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pacific Biosciences of backward and forwards among themselves. Pacific Biosciences' institutional investor refers to the entity that pools money to purchase Pacific Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2024-06-30 | 5.9 M | Millennium Management Llc | 2024-06-30 | 4.6 M | Goldman Sachs Group Inc | 2024-06-30 | 4 M | Capital World Investors | 2024-09-30 | 3.4 M | Northern Trust Corp | 2024-09-30 | 2.4 M | Soros Fund Management Llc | 2024-09-30 | 2.1 M | Charles Schwab Investment Management Inc | 2024-09-30 | 2 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 1.9 M | Bank Of America Corp | 2024-06-30 | 1.9 M | Ark Investment Management Llc | 2024-09-30 | 33.4 M | Blackrock Inc | 2024-06-30 | 23.6 M |
Pacific Biosciences' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 529.77 M.Market Cap |
|
Pacific Biosciences' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.37) | (0.39) | |
| Return On Capital Employed | (0.20) | (0.21) | |
| Return On Assets | (0.18) | (0.18) | |
| Return On Equity | (0.44) | (0.46) |
Determining Pacific Biosciences' profitability involves analyzing its financial statements and using various financial metrics to determine if Pacific Biosciences is a good buy. For example, gross profit margin measures Pacific Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Pacific Biosciences' profitability and make more informed investment decisions.
Please note, the presentation of Pacific Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Pacific Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Pacific Biosciences' management manipulating its earnings.
Evaluate Pacific Biosciences' management efficiency
Pacific Biosciences has return on total asset (ROA) of (0.1061) % which means that it has lost $0.1061 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.648) %, meaning that it created substantial loss on money invested by shareholders. Pacific Biosciences' management efficiency ratios could be used to measure how well Pacific Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.39. In addition to that, Return On Capital Employed is expected to decline to -0.21. At present, Pacific Biosciences' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 1.1 B, whereas Non Currrent Assets Other are forecasted to decline to about 3.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.77 | 2.90 | |
| Tangible Book Value Per Share | (0.86) | (0.90) | |
| Enterprise Value Over EBITDA | (11.69) | (11.11) | |
| Price Book Value Ratio | 3.55 | 4.30 | |
| Enterprise Value Multiple | (11.69) | (11.11) | |
| Price Fair Value | 3.55 | 4.30 | |
| Enterprise Value | 2.2 B | 1.8 B |
Pacific Biosciences showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Beta 2.009 |
Basic technical analysis of Pacific Stock
As of the 26th of November, Pacific Biosciences holds the Coefficient Of Variation of 1214.04, semi deviation of 5.87, and Risk Adjusted Performance of 0.072. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pacific Biosciences, as well as the relationship between them.Pacific Biosciences' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pacific Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pacific Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pacific Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Pacific Biosciences' Outstanding Corporate Bonds
Pacific Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Pacific Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Pacific bonds can be classified according to their maturity, which is the date when Pacific Biosciences of has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| PACIFIC BELL 7125 Corp BondUS694032AT09 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Pacific Biosciences' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Pacific Biosciences' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.072 | |||
| Market Risk Adjusted Performance | 0.2232 | |||
| Mean Deviation | 4.92 | |||
| Semi Deviation | 5.87 | |||
| Downside Deviation | 6.23 | |||
| Coefficient Of Variation | 1214.04 | |||
| Standard Deviation | 6.73 | |||
| Variance | 45.31 | |||
| Information Ratio | 0.0629 | |||
| Jensen Alpha | 0.236 | |||
| Total Risk Alpha | (0.52) | |||
| Sortino Ratio | 0.068 | |||
| Treynor Ratio | 0.2132 | |||
| Maximum Drawdown | 41.72 | |||
| Value At Risk | (10.16) | |||
| Potential Upside | 11.96 | |||
| Downside Variance | 38.83 | |||
| Semi Variance | 34.51 | |||
| Expected Short fall | (5.20) | |||
| Skewness | 0.8689 | |||
| Kurtosis | 3.05 |
| Risk Adjusted Performance | 0.072 | |||
| Market Risk Adjusted Performance | 0.2232 | |||
| Mean Deviation | 4.92 | |||
| Semi Deviation | 5.87 | |||
| Downside Deviation | 6.23 | |||
| Coefficient Of Variation | 1214.04 | |||
| Standard Deviation | 6.73 | |||
| Variance | 45.31 | |||
| Information Ratio | 0.0629 | |||
| Jensen Alpha | 0.236 | |||
| Total Risk Alpha | (0.52) | |||
| Sortino Ratio | 0.068 | |||
| Treynor Ratio | 0.2132 | |||
| Maximum Drawdown | 41.72 | |||
| Value At Risk | (10.16) | |||
| Potential Upside | 11.96 | |||
| Downside Variance | 38.83 | |||
| Semi Variance | 34.51 | |||
| Expected Short fall | (5.20) | |||
| Skewness | 0.8689 | |||
| Kurtosis | 3.05 |
Consider Pacific Biosciences' intraday indicators
Pacific Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Pacific Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 529473.0 | |||
| Daily Balance Of Power | 0.4167 | |||
| Rate Of Daily Change | 1.03 | |||
| Day Median Price | 1.9 | |||
| Day Typical Price | 1.88 | |||
| Price Action Indicator | (0.03) | |||
| Period Momentum Indicator | 0.05 |
Pacific Stock media impact
Far too much social signal, news, headlines, and media speculation about Pacific Biosciences that are available to investors today. That information is available publicly through Pacific media outlets and privately through word of mouth or via Pacific internal channels. However, regardless of the origin, that massive amount of Pacific data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Pacific Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Pacific Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Pacific Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Pacific Biosciences alpha.
Pacific Biosciences Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Pacific Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Pacific Biosciences Historical Investor Sentiment
Investor biases related to Pacific Biosciences' public news can be used to forecast risks associated with an investment in Pacific. The trend in average sentiment can be used to explain how an investor holding Pacific can time the market purely based on public headlines and social activities around Pacific Biosciences of. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Pacific Biosciences' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Pacific Biosciences and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Pacific Biosciences news discussions. The higher the estimate score, the more favorable the investor's outlook on Pacific Biosciences.
Pacific Biosciences Corporate Management
| Brett JD | General Secretary | Profile | |
| Stephen Turner | CoFounder CTO | Profile | |
| Susan Kim | Chief Officer | Profile | |
| Jeff Eidel | Chief Officer | Profile | |
| Denis Zaccarin | Senior Development | Profile | |
| Michele CPA | VP Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacific Biosciences of. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacific Biosciences. If investors know Pacific will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pacific Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.46) | Revenue Per Share 0.64 | Quarterly Revenue Growth (0.28) | Return On Assets (0.11) | Return On Equity (0.65) |
The market value of Pacific Biosciences is measured differently than its book value, which is the value of Pacific that is recorded on the company's balance sheet. Investors also form their own opinion of Pacific Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Pacific Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pacific Biosciences' market value can be influenced by many factors that don't directly affect Pacific Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Pacific Biosciences' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Pacific Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pacific Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.